Overview
The CLAA framework has been extended to cover cell and stem‑cell products, gene therapies and xenografts. The amendment, announced on 4 July 2026, closes a regulatory gap that allowed many clinics to market unproven stem‑cell cures. While the change does not guarantee immediate approval or lower prices, manufacturers must still prove safety, quality and efficacy under the Drugs and Cosmetics Act.
Key Developments
- Amendment revises Rules 75, 75A, 76 and 76A, and updates licensing forms (27D, 27DA, 28D, 28DA) to include advanced therapies.
- Both Central and State licensing authorities will jointly oversee manufacturing licences for these products.
- Regulatory coverage now includes regenerative treatments, CAR‑T cell therapy, gene‑replacement/editing products and animal‑tissue derived devices like heart valves.
- The move aims to curb unregulated clinics offering costly, unproven stem‑cell procedures for conditions like autism and spinal‑cord injury.
Important Facts
Until 2018, stem‑cell and cell‑based products were classified merely as “new drugs” without a dedicated licensing pathway. The amendment fills this void by providing a clear procedural route for manufacturers. Notable Indian advances include NexCAR19 by ImmunoACT, and ongoing CRISPR‑based gene‑editing projects such as CRISPR‑based therapy BIRSA‑101 for sickle‑cell disease being developed by CSIR‑IGIB and the Serum Institute.
Exam Relevance
Understanding this amendment is vital for GS2 (Polity) as it illustrates central‑state regulatory cooperation, and for GS3 (Health & Science) because it deals with emerging biotechnologies, their governance, and public‑health implications. Aspirants should note how policy adapts to scientific innovation and the challenges of balancing safety with access.
Way Forward
- Strengthen infrastructure for manufacturing and clinical trials to prevent bottlenecks.
- Develop a skilled workforce specialized in cell and gene therapy production.
- Monitor the impact of the new licensing regime on approval timelines and costs, especially for small biotech firms.
- Encourage transparent public communication to differentiate approved therapies from dubious clinic offerings.
While the amendment provides a formal pathway, broader systemic issues—limited facilities, workforce shortages, and research capacity—must be addressed to fully realise the benefits of advanced therapies for Indian patients.